Blueprint Medicines Soars 26% on $9.5 Billion Buyout. Why This Drug Is Key to the Deal.
Latest News
- Wells Fargo Stock Rises as Fed Lifts Asset Cap After 7 Years
- Nvidia-Backed CoreWeave Extends Record Rally Into Wednesday
- China increases scrutiny of rare earth magnets with new tracking system
- Analyst Report: Crowdstrike Holdings Inc
- Apple downgraded, Snowflake upgraded: Wall Street's top analyst calls
- Confidence Game: Share Buybacks Are Soaring. CEO Optimism Isn’t.